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The incubation period (IP) and the neuropathology of transmissible
spongiform encephalopathies (TSEs) have been extensively used to
distinguish prion isolates (or strains) inoculated into panels of
inbred mouse strains. Such studies have shown that the bovine
spongiform encephalopathy (BSE) agent is indistinguishable from
the agent causing variant Creutzfeldt–Jakob disease (vCJD), but
differs from isolates of sporadic CJD, reinforcing the idea that the
vCJD epidemic in Britain results from consumption of contaminated
beef products. We present a mouse model for genetic and envi-
ronmental factors that modify the incubation period of BSE cross-
species transmission. We have used two mouse strains that carry
the same prion protein (PrP) allele, but display a 100-day difference
in their mean IP following intracerebral inoculation with primary
BSE isolate. We report genetic effects on IP that map to four
chromosomal regions, and in addition we find significant factors of
host environment, namely the age of the host’s mother, the age of
the host at infection, and an X-cytoplasm interaction in the host.
Transmissible spongiform encephalopathies (TSEs) or priondiseases are fatal neurodegenerative disorders of the central
nervous system (CNS). They comprise a class of diseases that
include sheep scrapie, bovine spongiform encephalopathy
(BSE), and the human diseases Creutzfeldt–Jakob disease
(CJD), Gerstmann–Straussler–Scheinker syndrome, Kuru, and
Fatal Familial Insomnia. Prion diseases may present as familial,
acquired, or sporadic disorders, all of which involve an aberrant
metabolism of the prion protein (PrP) (1). The conversion of
cellular prion protein, PrPC, to the disease-specific protease-
resistant isoform, PrPSc, involves a conformational change,
whereby the a-helical content decreases and the amount of
b-sheet increases (2). The hallmark of prion diseases, whether
sporadic, familial, or acquired by infection, is the accumulation
of PrPSc in the extracellular space in the brains of humans and
animals that have contracted the disease.
Experimental transmission of prions in inbred mouse strains
has enabled the genetic analysis of prion disease expression.
Animals devoid of the gene encoding PrP (Prnp-deficient) do
not develop disease after transmission (3–5) and in transgenic
mice with higher copy numbers of Prnp, progression of the
disease is faster (6). All laboratory mouse strains tested contain
one of two forms of PrP—PrP A has leucine at residue 108 and
threonine at 189, whereas PrP B is 108 phenylalanine and 189
valine. The incubation period of the disease depends on the Prnp
genotype of the mouse (7), but the size and direction of this
effect differ according to the prion strain used (8, 9). However,
the host Prnp genotype does not account for all of the variation
seen in the incubation period, indicating that other genes are
involved in the control of the disease. An H-2D–linked locus,
named Pid1, and two loci on chromosomes 9 and 11, Pid2 and
Pid3, have been reported to affect the length of incubation
period in mouse passaged scrapie-infected mice (10, 11), but the
nature of the underlying genes remains to be determined.
Human PrP is also polymorphic in sequence. Homozygosity
for methionine at residue 129 seems to associate with disease
phenotype in acquired TSE. All tested victims of vCJD have
been homozygous for methionine at codon 129 of the PRNP gene
(12). In other acquired prion diseases, such as Kuru, homozy-
gosity for methionine is overrepresented in the younger age
groups, whereas heterozygosity with valine 129 is more prevalent
in the older age groups (13). Sporadic cases of CJD have been
reported to be more common in homozygotes for either valine
or methionine at codon 129 than in heterozygotes (14). The
codon 129 polymorphism also influences the phenotype of
familial disease associated with an aspartic acid to asparagine
mutation at codon 178 of the human PRNP gene (15).
One of the main characteristics of prion diseases is the long
incubation period, which could be explained by a slow but
controlled proliferation and transport of the infectious agent.
Accumulating evidence suggests that, following exposure to
infection by a peripheral route, replication usually takes place in
the host’s lymphoid organs preceding replication in the CNS. For
transmission of BSE from cattle to mice, and some other
interspecies transmissions, a replication phase in peripheral
tissues appears to be obligatory before neuroinvasion can occur,
even when infection is introduced directly into the brain (16, 17).
Whether modifier genes of prion incubation period affect the
replication rate of the infectious agent, the susceptibility of the
host to the pathogenic effects of prion replication, or both
remains unclear.
Given the likely link between vCJD and cattle BSE, we
attempted to detect and map modifier genes for BSE incubation
period by means of experimental transmission to mice. To avoid
any effect of the coding region of the Prnp gene, we used
C57BLyFayDk and RIIIyFayDk mouse strains, both of which
carry the Prnpa allele. Following intracerebral (i.c.) challenge
with BSE inoculum, C57BL and RIII mouse strains have a
100-day difference in incubation period (16, 18). It has been
shown, however, that C57BL and RIII mice differ in the Prnp
promoter region (H. Baybutt and J.M., unpublished observa-
tion), leaving open the possibility that different Prnp expression
levels may be associated with incubation period. In addition, the
two strains differ in their haplotypes on the H-2D region,
enabling us to test whether there are detectable H-2D linked
effects on BSE incubation period.
Materials and Methods
Crosses. Reciprocal crosses between C57BL and RIII strains
were performed. The F1 animals are named CR or RC depend-
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ing on whether the maternal strain was C57BL or RIII, respec-
tively. F1 females were backcrossed to either strain giving four
backcross populations (CRC, CRR, RCC, and RCR). In total,
1,200 backcross animals were generated, 300 in each backcross.
Inocula Preparation. Brain tissue was collected from seven ter-
minally affected cows with histopathologically confirmed BSE.
The tissue was homogenized in physiological saline at 10%
concentration.
Infections. All 1,200 backcross mice and 30 animals from each
parental strain and from reciprocal F1s were challenged intra-
cerebrally with BSE inoculum, in three cohorts. Mice were
anaesthetized by halothane inhalation and injected intracere-
brally with 0.02 ml of inoculum at 3 to 8 weeks of age. All animals
were housed under SPF conditions, monitored daily for signs of
intercurrent illness, and, from 250 days after BSE challenge,
were subject to a formal clinical monitoring system (19). Animals
then were checked daily and scored weekly by an experienced
observer for clinical signs of TSE-like disease, using well estab-
lished criteria that have previously been shown to give precise
and reproducible measurements of incubation period in an
extensive range of TSE studies. Animals were killed after three
consecutive weekly scores of ‘‘definitely affected’’ or when there
was a significant deterioration between scoring days. About 85%
of the animals in each injection group eventually developed a
TSE disease. The remaining 15% were killed or died with
intercurrent disease throughout the course of the experiment.
Because the maximum incubation periods seen in mice that did
develop BSE were very long, few, if any, of the 15% can be
regarded as true survivors. Clinical diagnosis was, in all cases,
confirmed by histopathological examination of the brains of the
mice.
Incubation period measurement was calculated as the interval
between injection and a standard clinical end-point when the
mice were showing clear signs of neurological disease, as
described (19).
DNA Isolation and Genotyping. Genomic DNA was isolated from
tail snips. Approximately 1y2 inch of tail was removed during the
electronic tagging session of the animals. Tail tips were incu-
bated overnight at 55°C in 1 ml of extraction buffer (0.05 M
TriszHCly0.1 M EDTAy1% SDS) containing 500 mg/ml protein-
ase K. The samples were then extracted with phenol-chloroform.
High molecular weight DNA was obtained after ethanol pre-
cipitation and redissolved in 200 ml TE (10 mM Trisy1 mM
EDTA, pH 7.5). DNA for genotyping was resuspended in
distilled water at 30 ng/ml. The most polymorphic microsatellite
markers among inbred mouse strains were selected, based on the
MIT database (http:yywww.genome.wi.mit.edu). Absolute and
relative distance between the markers on the chromosomes was
estimated from the Mouse Genome Database (http:yy
www.informatics.jax.org), and a panel of 150 markers was tested
on DNA from the parental strains. Final genotypes were ob-
tained for 90 markers spread throughout the genome. PCR
products were amplified by using optimized multiplex condi-
tions. Genotypes were assayed and scored in an ABI 310
capillary system (Applied Biosystems).
Linkage analysis was performed by using the GeneLink pack-
age (20). Retyping of double recombinants was performed for all
intervals. The average distance between markers is 17 cM. A list
of the markers used and genetic maps are available from the
authors.
Statistical analysis was carried out by using the software
package MINITAB, version 13.1 (Minitab, State College, PA). The
regression of the variance on the means across groups at this
scale of measurement gave x 5 8 1 0.101y, where x is the
standard deviation of the group and y is the mean incubation
period. To establish independence of the variance and the
means, the transformation ln(y 1 8y0.101) was used to calculate
the individual data points that were entered for further analysis.
The age of mice at injection (B week) and the age of the mother
at birth of those animals (M week) were fitted as covariates for
the regression model. Goodness of fit was judged based on a lack
of fit test calculated by the program.
Interaction between maternal and X-chromosome effects
were obtained as Iij 5 zij 2 Gi 2 Ej, where i represents the
columns and j the rows of Table 2. Gi is the mean within each
column and Ej is the deviation of the mean within rows from the
F1 population mean (mG) (21). Ej represents the maternal effects,
and the deviation of Gi from mG represents the X-chromosome
effects.
Qantitative trait loci (QTL) mapping was performed by using
the software package QTL CARTOGRAPHER, version 1.01 (http:yy
statgen.ncsu.eduyqtlcarty). Interval mapping results were com-
pared with the results obtained by MAPMANAGERQTX7B (http:yy
mcbio.med.buffalo.eduymmQTX.html) and QTL CAFE´ (http:yy
web.bham.ac.ukyg.g.seatony). Composite interval mapping
results were compared between QTL CARTOGRAPHER and QTL
CAFE´, using the option for linked QTL. Estimates of locations
and effects from the different packages were in agreement.
Genome-wide significance levels were obtained by running 1,000
permutations on MAPMANAGERQTX7B. Epistatic interactions
between pairs of loci were assessed by using the program EPISTAT
(http:yywww.larklab.4biz.netyepistat.htm).
Results
The mean incubation period in these experiments was 541 days
for the C57BL strain and 441 days for the RIII strain. This is in
accord with previous studies showing the two strains to have one
hundred days difference in their mean IP following primary BSE
transmission (16, 18). However, in our present study the mean IP
in these strains is longer than previously reported, indicating a
relatively low titer of BSE in the inoculum. Table 1 summarizes
the mean IP data for the parental strains, F1 progeny and the
backcross populations. The parental strains and three of the four
backcross populations do not have a significant difference in
mean IP between males and females. However, the F1 animals
do have a significant sex difference, with males having a signif-
icantly longer mean IP than females. The F1 male IP was not
significantly different from the value midway between the two
Table 1. Sex specific effects on IP
Population Sex n Mean 95% c.i. SD P
C57BL F 23 545 42.5–84.9
M 12 535 44.3–121.1 ns
RIII F 19 440 34.8–75.2
M 14 443 38.4–96.1 ns
CxR F 17 425 33.9–79.3
M 15 488 43.2–104.2 0.002
RxC F 12 462 29.1–79.5
M 14 506 33.0–82.6 0.02
RCxC F 118 517 58.8–67.4
M 140 518 53.8–70.4 ns
CRxC F 116 526 53.9–61.9
M 141 513 51.9–68.0 ns
CRxR F 121 465 56.5–75.5
M 132 461 48.6–64.2 ns
RCxR F 121 465 54.9–73.5
M 138 446 48.7–63.9 0.01
Mean IP and 95% confidence intervals of the standard deviation for the
parental strains, F1 progeny, and backcross populations. P values are for
differences between males and females from the same population. ns, not
significant.






parental strains. However, F1 females, from crosses in either
direction, had a mean IP significantly shorter than the equivalent
males. One of the four backcross populations also had significant
sex-specific differences. In addition, the data indicate that the
phenotypic variance across the whole backcross generation is not
statistically different from the variance of the parental strains
and F1 animals.
F1 Sex Differences: X Chromosome and Cytoplasm Interaction. Each
F1 population is genetically identical, apart from X-chromosome
dosage in females and the Y chromosome in males. The sex
differences in IP in the F1 populations may be due to an effect
of the X chromosome. It should normally be possible to measure
this effect simply by comparing F1 males with different X
chromosomes (i.e., with different strain mothers, from the
reciprocal crosses), but these males also have a different mater-
nally derived cytoplasm and maternal environment. We can
demonstrate that there is a statistically significant maternal
effect, because genetically identical female F1 animals show a
37-day difference in mean IP depending on the maternal strain
(females with RIII mother and C57BL father have an IP of 462
days, those with C57BL mother and RIII father have an IP of 425
days). The effect of the X chromosome, then, can only be
determined after subtraction of the maternal effect. In Table 2
we show the mean IP of reciprocal F1s and dissect out the relative
maternal and X-linked effects associated with each parental
strain (see Materials and Methods). Both effects are clearly
present, but their magnitudes are subject to large statistical error
due to the relatively small sample size. The maternal effect
associated with the RIII strain prolongs the IP by ’14 days,
whereas the RIII strain X-chromosome (XR)-linked effect acts
in the opposite direction and shortens the IP by about 5 days.
However, when both the X chromosome and the maternal effect
are of the same strain of origin, the effect seen is not an addition
of the two effects (which would be a longer IP by ’9 days), rather
their interaction prolongs the IP by almost 27 days. Hence, when
the X chromosome and cytoplasm are from the same strain, the
F1 animals have a longer IP. F1 females have a significantly
shorter IP because there is a deleterious interaction between the
maternal effect of one strain with an X chromosome of a
different strain. F1 males always inherit both the X chromosome
and the cytoplasm from the mother (same inbred strain), escape
the deleterious effect of this interaction, and have prolonged IP
in comparison to their sisters. It is possible that the X-linked
effect reflects a parent of origin rather than a strain of origin
effect. The F1 data cannot distinguish between the two possi-
bilities, but the data in the backcross generation are compatible
with the simpler explanation of a strain-of-origin hypothesis.
According to this scenario no sex-specific differences are ex-
pected in the backcross generation because, during F1 female
meiosis, recombination and Mendelian segregation of the X
chromosome will ensure in the progeny that the same proportion
of both sexes experience the effects of the deleterious interac-
tion. Three of the four backcrosses showed no sex-specific effect.
The RCR backcross did have an effect, the reverse of that seen
in the F1, such that females had a prolonged mean IP compared
with males. In this cross, transmission ratio distortion resulted in
an excess of maternally inherited XR alleles among the females.
These alleles, combined with a cytoplasm of RIII origin, led to
an excess of prolonged IP among females on average, because
fewer female progeny experienced the deleterious X-cytoplasm
interaction in comparison to males.
Age Effects. Segregation of genes during F1 meiosis should
normally increase the phenotypic variance in the backcross
generation. Unexpectedly, we find that this is not the case. Two
explanations could account for the restricted variance in the
backcross populations. Either the heritability of the trait is low
or there is negative correlation between particular individuals
(shortylong IP) with respect to macroenvironment (age groups,
maternal effects, litter size, etc.). In the latter case, such a
nonrandom distribution can create a negative covariance term,
which masks the true genetic variance present in the backcross
populations (21). In fact, we detect significant effects of age on
the IP. Both the age of the mice at the time of injection and,
surprisingly, the maternal age at birth of these animals were
negatively correlated with the length of the IP (P , 0.001). Our
data suggest that the purely genetic component of the trait is only
3% greater than the negative covariance term, made up of the
geneticyenvironmental correlation, and thus the variance result-
ing from genetic factors is effectively masked.
Genetic Factors. Taking into account the effects described above,
we can then model the genetic factors acting on the backcross
population. Table 1 shows that groups having shorter IP tend to
also have smaller phenotypic variance. This phenomenon makes
the original measurement scale statistically inappropriate and we
used a transformation (see Materials and Methods) to treat the
data. Table 3 shows the results of the regression analysis on the
individual IP data collected from all populations. As expected,
the X-cytoplasm interaction, the age of the mice at the time of
injection, and the age of the mother at birth of the offspring are
Table 2. Relative magnitudes of maternal and X-linked effects




R 506 462 113.75
C 425 488 213.75
X effect 24.75 14.75
Interactions: maternal effect 1 X-chromosome effect
R1R or C1C 126.75 days
R1C or C1R 226.75 days
Calculated from untransformed IP data of F1 animals. Incubation period in
days are shown in rows corresponding to their maternal environment (cyto-
plasm or uterine) and in columns corresponding to their X chromosome. The
effects in days are shown in the final column (for maternal effect) and final
row (X-chromosome effect). Below we indicate the effect of interaction
between X chromosome and environment, calculated as described in Mate-
rials and Methods.
Table 3. Coefficients for predictor variables by regression
analysis on the individual transformed IP data collected from
all populations
Predictor Coefficient SE coefficient T-statistic P
Parametric mean 6.74641 0.04897 137.77 ,0.0005
a 0.08796 0.01235 7.12 ,0.0005
Mw 20.0069118 0.0009951 26.95 ,0.0005
Bw 20.010302 0.001350 27.63 ,0.0005
d 20.32255 0.05198 26.21 ,0.0005
axa 20.33601 0.05293 26.35 ,0.0005
I 0.05143 0.01337 3.85 ,0.0005
axd 0.05433 0.02844 1.91 0.056
cyt 20.007184 0.003701 21.94 0.052
a, additive effects; Mw, the age of the mother at the birth of the injected
animals in weeks; Bw, the age of the mice at injection in weeks; d, dominance
effects; axa, epistatic interaction between loci with additive effects; I, mater-
nal and X-chromosome interactions; axd, epistatic interaction between loci
with additive and dominant effects; cyt, effect of cytoplasm.
7404 u www.pnas.orgycgiydoiy10.1073ypnas.121172098 Manolakou et al.
all statistically significant and must be included in the final
model.
We find that single gene effects due to both additive gene
action and gene dominance are significant, but that dominance
contributes 4-fold more to the phenotype. Epistasis (gene in-
teraction) between additive genes contributes as much as dom-
inance to the phenotype, and the fact that the epistatic term is
negative indicates that genes of opposite effects (long and short
IP genes) are present in each parental strain (i.e., there is gene
dispersion). Finally, effects linked to the cytoplasm and to more
complex epistatic interactions, although of marginal signifi-
cance, are required for model fitting.
QTL Mapping. The genetic model has allowed us to go on to map
QTLs in the backcross populations. Each backcross animal was
genotyped at 90 loci distributed throughout the genome on all
chromosomes. QTL analysis was initially performed separately
for each backcross. Because similar results were obtained for
backcrosses to the same inbred parent (data not shown), we
grouped them and present the results of the combined analysis.
Fig. 1 shows the QTLs detected in the backcrosses to C57BL (A
and B) and RIII (C and D). All detected QTLs are dominant,
because they were detected only in one direction of cross, with
C57BL alleles contributing to a longer and RIII alleles to a
shorter IP. All detected QTLs were either significant (chromo-
some 15) or highly significant (chromosomes 2, 4, and 8) for a
genome-wide probability. The effects of individual QTLs on the
phenotype are only moderate, each explaining 4–7% of the total
phenotypic variance. After correction for dominance, the cu-
mulative effects from the detected QTLs account for 50% of the
initial difference between the parental strains. The relatively
weak effects of the individual QTLs produce rather poor genetic
localization (22), with 95% confidence intervals ranging from 10
to 25 cM.
The regression model indicated that epistatic interactions
between loci are an important component of the length of IP.
However we could not detect them in our sample, which suggests
that, although a number of interactions might be present, their
Fig. 1. Lod score plots for BSE incubation period in
backcross populations. (A and B) Animals back-
crossed to C57. (B and C) Animals backcrossed to RIII.
The x axes indicate the chromosomal linkage maps in
centimorgans, based on recombination frequencies
calculated by using Gene-Link. (A, chromosome 2; B,
chromosome 8; C, chromosome 4; D, chromosome
15). The first marker analyzed on each chromosome
is positioned at 0 cM. The y axes indicate lod scores
for intervals containing putative QTLs affecting BSE
incubation period based on composite interval map-
ping by using QTL CARTOGRAPHER. One lod, 95% confi-
dence intervals, are indicated by the double-headed
arrows. The dotted lines intersecting the y axes in-
dicate the lod score representing statistical signifi-
cance for the respective data sets (A and B, 2.71; C
and D, 2.50). Additive effects calculated by QTL CAR-
TOGRAPHER are plotted beneath (not corrected for
dominance).






effects do not reach statistical significance when pairs of loci are
considered separately. This lack of detectable epistatic interac-
tions includes markers on chromosome 2, in the proximity of the
Prnp gene.
Discussion
The four QTLs we detect only explain 50% of the 100-day
difference between the parental strains and none accounts for
more than 7% of the total phenotypic variance. With our sample
size, a QTL explaining less than 3% of the phenotypic variance
would not have been detected as significant (23). Hence, the
remaining 50% of the difference between the parental strains
must be due to epistatic interactions that do not reach signifi-
cance, to a number of undetected single QTLs, or to a combi-
nation of these. If there are undetected single QTLs that
determine the length of IP, which display no dominance and
explain about 3% of the phenotypic variance each, then there
must be no fewer than four of them. In this case about 700 F2
animals will be required to map them in 25 cM 95% confidence
intervals (24). If they display dominance, the number of unde-
tected QTLs is higher, and at least 700 backcross animals will be
needed to detect them. However, because the direction of
dominance is not known a priori, 700 animals in each backcross
direction would be required. If epistatic interactions determine
most of the remaining difference, and given that they are weak,
then a very large F2 cross (.1,000 animals) is required to detect
them, but it is doubtful that we will be able to identify the
individual genes implicated.
Our study of primary BSE transmission to mice gives con-
trasting results with a recent study on the incubation period in
mice challenged intracerebrally with mouse-passaged scrapie. In
both studies parental strains were used that both carry the Prnpa
allele. The results for mouse-passaged scrapie indicate a few
genes of additive gene action contributing to the phenotype,
whereas ours indicate that IP is a polygenic trait subject to
dominance. None of the mapped QTLs in the two studies is
found on the same chromosome. However, because our study
crosses a species barrier between cattle and mouse (whereas the
other study does not), differences in pathogenesis are likely to
underlie the different results obtained. In intraspecies transmis-
sions (mouse-passaged scrapie to mice), an intracerebral injec-
tion establishes infection directly in the brain, resulting in a
relatively short IP (approximately two thirds of the IP following
i.p. challenge) (8); genetic effects are therefore likely to operate
within the CNS. In contrast, in some interspecies transmissions,
including the transmission of cattle BSE to mice, the IPs
following intracerebral and peripheral challenge are approxi-
mately equal (16). Furthermore, immunodeficient mice are
relatively resistant to BSE challenge, even by the intracerebral
route (17). These studies suggest that, in the presence of a species
barrier, the BSE agent must be processed in peripheral tissues
before it can infect the nervous tissue. Therefore, genetic effects
in our BSE study could operate in both peripheral tissues and
the CNS.
Previous studies have shown that RIII and C57BL mice are
equally susceptible to BSE infection and that the same strain of
agent is isolated in each mouse strain (16, 18). Infectivity can
accumulate in all components of the lymphoreticular system
(LRS) and experimental evidence points toward the follicular
dendritic cells as the likely cell type that could support prion
replication in the LRS (25). The spread of infectivity from the
LRS to CNS is probably accomplished via peripheral nerves, to
the spinal cord from where it finally ascends to the brain. Other
studies (C.F., unpublished work) indicate that the difference in
IP seen between C57BL and RIII strains after i.c. inoculation
results from a difference in the timing of BSE replication in these
tissues.
Our study indicates that there are a number of chromosomes
with minor effects on the phenotype rather than a few major
ones. Given the relatively weak effects of the detected QTLs and
the rather large confidence intervals, it is not straightforward to
pinpoint candidate genes in these regions. Based on the obser-
vations mentioned above involving the two parental strains, we
can speculate about the mode of action of these genes. It is
interesting to note that the mouse homologue of the human
intestinal DPP4 gene that encodes a T lymphocyte activating
molecule, which is a cell-surface antigen with peptidase activity,
maps within the 95% C.I. on chromosome 2. The IFN a and b
families are located near to the most likely position for the QTL
on chromosome 4. Scya17, which encodes for a chemokine that
specifically attracts CD41 T helper type 2 lymphocytes in
lymphoid and nonlymphoid organs, is located at the most likely
position for the QTL on chromosome 8. Finally, at the most
likely position of the QTL on chromosome 15 is found the Ly6
complex (Ly6A-Ly6D). Antigens encoded by this complex are
present on peripheral T and B cells of spleen and lymph nodes
and bone marrow. However, there is no independent support
from other studies that any of these genes are indeed involved in
prion replication andyor the length of incubation period of the
disease. Given the rather large confidence intervals, the possi-
bility cannot be excluded that other genes located in these
intervals are underlying the mapped QTLs. For instance, on
chromosome 8, within the 95% confidence interval, maps a
family of metallothioneins (Mt1-Mt3), which are thought to play
an important role in heavy-metal detoxification and metabolism,
such as Cu11. Early studies showed that cuprizone, a copper
chelating agent, induces neuropathological changes in mice
similar to those found in prion diseases (26), suggesting a role for
copper in the pathology of prion diseases. More recently, an
octapeptide repeat in the N-terminal region of the prion protein
has been shown to bind copper (27), and upon binding the
protein appears to have a more defined structure in this region,
which promotes the conformational shift from an a-helical to a
b-sheet structure (28). There is also evidence from Prnp-
deficient mice that their cerebellar cells have an increased
sensitivity to the toxicity of copper-containing salts (29), a
marked decrease in membrane copper content, and decreased
activity of superoxide dismutase 1 (30, 31), suggesting that the
prion protein may play a role in copper homeostasis in the CNS.
The role of copper in other neurodegenerative diseases raises the
possibility of a common neurodegenerative process linked to
copper homeostasis and transport (32).
The H-2D–linked effect, initially detected in congenic mouse
strains infected with mouse-adapted CJD, has failed to be
replicated by us or other investigators (33, 34). Finally, although
we do know that there are differences in the promoter region of
the Prnp gene between the C57BL and RIII mouse strains, we
do not detect any effect linked to the Prnp gene. The QTL
detected on Chr 2 is situated about 40 cM proximal to Prnp,
which is not included in the 95% confidence interval. If expres-
sion level differences were associated with the known polymor-
phism at the promoter region, and this in turn was related to the
length of IP, then we would expect to detect a QTL in the vicinity
of Prnp.
Experimental prion transmissions in mice have been invalu-
able for our understanding of prion biology and disease devel-
opment. However, different studies reveal different genetic
contributions to disease susceptibility. Each combination of
inbred strains contains only a limited genetic variability com-
pared with natural populations, and it is unlikely that all genes
affecting the IP in natural populations will be revealed by studies
like these. Additional complexity is added, because development
of the disease is already known to depend on the agent used for
the infections (prion strain), the host’s environment, and the
species involved as source and recipient of the infectious particle
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(species barrier). Extrapolations to acquired human prion dis-
ease have to take into account all of these limitations. These
caveats notwithstanding, our findings imply that susceptibility to
the disease is polygenic and that the population frequency for at
least eight genes other than PrP is likely to affect incubation
period. This conclusion is important from an epidemiological
point of view because predictions about the possible number of
future vCJD victims have been made by assuming a sole genetic
risk associated with certain PRNP genotypes (MM homozy-
gotes). However, if the incubation period for vCJD is polygenic
and assuming Hardy–Weinberg equilibrium for the different
alleles, the frequency of the most susceptible genotype will be
lower than currently believed.
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